HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

RemeGen Co Ltd (9995.HK) - Here Are the Strength and Concerns After Commercialization

Pre-IPO MicroTech Medical (Hangzhou) - The Main Products, the Business and the Challenges

Pre-IPO Neusoft Medical Systems - Promising Market but Full of Challenges

Shanghai Junshi Bioscience - Here Are the Challenges

Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?

CStone Pharma (2616.HK) - It Is the Time to Revalue the Company

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Hutchmed China Ltd / Equity Capital Markets

<p>In March this year, the CEO of <a href="https://www.smartkarma.com/entities/hutchison-china-meditech-ltd-7c2c4b58-ca71-4ac4-befb-345e8d0f10ca" target="_blank" data-smartkarma-citation="entities:27342:1" rel="noopener">Hutchison China MediTech Ltd (HCM US)</a> said at its 2020 earnings conference that the Company has no plans for an IPO in Hong Kong. Just three months later, on June 18, <a href="https://www.smartkarma.com/entities/hutchmed-china-ltd" target="_blank" data-smartkarma-citation="entities:133:1" rel="noopener">Hutchmed China Ltd (13 HK)</a> formally passed the HKEX hearing for its IPO. After listing in the UK and the US, Hutchmed has made its way to Hong Kong after all. However, those leading listed domestic biopharmaceutical companies have already started their commercialization of products, and the construction of supporting capabilities such as sales team and production capacity is also under way. Therefore, in the context of fierce domestic innovative drug competition, it is not clear whether Hutchmed can perform well based on its pipeline and commercialization capabilities. This insights mainly analyzed both the strength and the concerns of the Company.</p>

In March this year, the CEO of Hutchison China MediTech Ltd (HCM US) said at its 2020 earnings conference that the Company has no plans for an IPO in Hong Kong. Just three months later, on June 18, Hutchmed China Ltd (13 HK) formally passed the HKEX hearing for its IPO. After listing in the UK and the US, Hutchmed has made its way to Hong Kong after all. However, those leading listed domestic biopharmaceutical companies have already started their commercialization of products, and the construction of supporting capabilities such as sales team and production capacity is also under way. Therefore, in the context of fierce domestic innovative drug competition, it is not clear whether Hutchmed can perform well based on its pipeline and commercialization capabilities. This insights mainly analyzed both the strength and the concerns of the Company.

Pre-IPO Hutchmed China Ltd (13.HK) - The Strength and the Concerns